Physician profile
Michael Garrett
NPI 1699162495
$644.75
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $41.31.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $180.20 | 2019 | |
| Insmed, INC. | $114.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.49 | 2019-2020 | |
| Pfizer INC. | $79.15 | 2019 | |
| Merck Sharp & Dohme LLC | $73.97 | 2019-2020 | |
| Gilead Sciences, INC. | $30.62 | 2019 | |
| Becton, Dickinson and Company | $27.64 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.43 | 2019 | |
| Glaxosmithkline, LLC. | $13.21 | 2019 | |
| Shire North American Group INC | $11.34 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.